Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT01946711
- Locations
- 🇩🇪
HNO-Zentrum Mangfall-Inn, Rosenheim, Germany
🇩🇪University LMU Munich, Munich, Germany
🇩🇪University Göttingen, Göttingen, Germany
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01912872
- Locations
- 🇲🇽
Novartis Investigative Site, Mérida, Yucatán, Mexico
Evaluation of Inhaled Treatment in Sinusitis
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2014-01-27
- Target Recruit Count
- 50
- Registration Number
- NCT01907204
Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Saeed Abbasi
- Target Recruit Count
- 90
- Registration Number
- NCT01854515
- Locations
- 🇮🇷
Alzahra University Hospital, Isfahan, Iran, Islamic Republic of
Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Azienda Policlinico Umberto I
- Target Recruit Count
- 64
- Registration Number
- NCT01846962
- Locations
- 🇮🇹
Departments of Pediatrics, Sapienza - University of Rome, Rome, Italy
Effect of Nebulized Budesonide on Preventing Postextubation Complications in Critically Patients
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT01786070
- Locations
- 🇮🇷
Alzahra University Hospital, Isfahan, Iran, Islamic Republic of
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 61
- Registration Number
- NCT01783821
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Antibiotics and Hydroxychloroquine in Crohn's
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Royal Liverpool University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT01783106
- Locations
- 🇬🇧
Royal Liverpool and Broadgreen Unversity Hospitals Trust, Liverpool, Merseyside, United Kingdom
Effects of Symbicort on the Ventilatory Kinematics
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 9
- Registration Number
- NCT01712854
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma
- Conditions
- Interventions
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Target Recruit Count
- 181
- Registration Number
- NCT01676987
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.